Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

These findings suggest that the combination of olverembatinib and blinatumomab offers promising clinical benefits and an optimal safety profile in patients with Ph+ or Ph-like ALL, thus representing a ...

The VEDOSS project has previously shown that 70% of patients with Raynaud's phenomenon and at least one red flag – systemic ...

"The results of this phase 2 trial establish the potential for ziftomenib to induce responses and prolong life in responding patients with relapsed or refractory acute myeloid leukemia ...

May 30, 2025 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, today announced it will present two posters ...

Background The aim of the study was to better characterise the immunological origin and the behaviour of interleukin (IL)-23-responsive innate lymphoid cells (ILCs) in the gut, synovial fluid (SF) and ...